Oncolytics Biotech (NASDAQ:ONCY) doses first patient in its phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC).
The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA (OTCPK:MKGAY) and Pfizer (NYSE:PFE).
Participants will receive paclitaxel, pelareorep
in combination with paclitaxel alone, or pelareorep in combination with
paclitaxel and Merck and Pfizer’s anti-PD-L1 checkpoint inhibitor,
avelumab (Bavencio). The BRACELET-1 study will enroll 45 patients
randomized into three cohorts.
The primary endpoint is overall response rate.
Exploratory endpoints include peripheral and tumor T cell clonality,
inflammatory markers, and safety and tolerability assessments.
https://seekingalpha.com/news/3585332-dosing-underway-in-oncolytics-bio-combo-study-in-breast-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.